Literature DB >> 26249525

Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection.

Toshihiro Kitajima1, Etsuro Hatano2, Yusuke Mitsunori2, Kojiro Taura2, Yasuhiro Fujimoto2, Masaki Mizumoto2, Hideaki Okajima2, Toshimi Kaido2, Sachiko Minamiguchi3, Shinji Uemoto2.   

Abstract

We report the first case of initially unresectable advanced hepatocellular carcinoma (HCC) with portal vein and hepatic venous tumor thrombosis and multiple lung metastases that allowed for curative hepatectomy after multidisciplinary treatment including sorafenib. A 54-year-old male presented with a large HCC in the right liver with tumor thrombosis of the left portal vein and middle hepatic vein (MHV) as well as multiple lung metastases. His serum alpha-fetoprotein level was elevated at 52,347 ng/mL and palliative treatment with sorafenib was initiated. One month later, a significant reduction in the serum AFP level, decrease in the tumor size with recanalization of the portal vein and the absence of lung metastases were noted. Three months after the start of sorafenib treatment, external-beam radiotherapy was performed to treat enlargement of the area of MHV thrombosis, and the thrombosis regressed. Five months after the initiation of sorafenib treatment, central bisegmentectomy associated with removal of the tumor thrombus in the inferior vena cava was performed. A microscopic examination revealed complete necrosis of the tumor. Sorafenib treatment may be a bridge to curative resection in selected patients with initially unresectable advanced HCC, even in cases involving multiple extrahepatic metastases.

Entities:  

Keywords:  Complete response; Hepatectomy; Hepatocellular carcinoma; Lung metastases; Sorafenib

Mesh:

Substances:

Year:  2015        PMID: 26249525     DOI: 10.1007/s12328-015-0594-7

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  16 in total

1.  Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma.

Authors:  Yu-Yun Shao; Zhong-Zhe Lin; Chiun Hsu; Ying-Chun Shen; Chih-Hung Hsu; Ann-Lii Cheng
Journal:  Cancer       Date:  2010-10-01       Impact factor: 6.860

Review 2.  Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.

Authors:  Masatoshi Kudo; Kazuomi Ueshima
Journal:  Oncology       Date:  2010-07-08       Impact factor: 2.935

Review 3.  The global epidemiology of hepatocellular carcinoma: present and future.

Authors:  Katherine A McGlynn; W Thomas London
Journal:  Clin Liver Dis       Date:  2011-05       Impact factor: 6.126

4.  Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection.

Authors:  Sabine Irtan; Xavier Chopin-Laly; Maxime Ronot; Sandrine Faivre; Valérie Paradis; Jacques Belghiti
Journal:  Liver Int       Date:  2011-01-11       Impact factor: 5.828

5.  Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening.

Authors:  Eric T Sawey; Maia Chanrion; Chunlin Cai; Guanming Wu; Jianping Zhang; Lars Zender; Alice Zhao; Ronald W Busuttil; Herman Yee; Lincoln Stein; Dorothy M French; Richard S Finn; Scott W Lowe; Scott Powers
Journal:  Cancer Cell       Date:  2011-03-08       Impact factor: 31.743

6.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Authors:  Ann-Lii Cheng; Yoon-Koo Kang; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Suk Kim; Rongcheng Luo; Jifeng Feng; Shenglong Ye; Tsai-Sheng Yang; Jianming Xu; Yan Sun; Houjie Liang; Jiwei Liu; Jiejun Wang; Won Young Tak; Hongming Pan; Karin Burock; Jessie Zou; Dimitris Voliotis; Zhongzhen Guan
Journal:  Lancet Oncol       Date:  2008-12-16       Impact factor: 41.316

7.  Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.

Authors:  Thomas Yau; Pierre Chan; Kelvin K Ng; Sin Ho Chok; Tan To Cheung; Sheung Tat Fan; Ronnie T Poon
Journal:  Cancer       Date:  2009-01-15       Impact factor: 6.860

8.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

9.  Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma.

Authors:  Shang-Wen Chen; Li-Ching Lin; Yu-Cheng Kuo; Ji-An Liang; Chia-Chun Kuo; Jeng-Fong Chiou
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-04-01       Impact factor: 7.038

10.  Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib.

Authors:  Sabrina Kermiche-Rahali; Aude Di Fiore; Fanny Drieux; Frédéric Di Fiore; Arnaud François; Michel Scotté
Journal:  World J Surg Oncol       Date:  2013-08-02       Impact factor: 2.754

View more
  6 in total

1.  Impact of surgical treatment after sorafenib therapy for advanced hepatocellular carcinoma.

Authors:  Hideaki Takeyama; Toru Beppu; Takaaki Higashi; Takayoshi Kaida; Kota Arima; Katsunobu Taki; Katsunori Imai; Hidetoshi Nitta; Hiromitsu Hayashi; Shigeki Nakagawa; Hirohisa Okabe; Daisuke Hashimoto; Akira Chikamoto; Takatoshi Ishiko; Motohiko Tanaka; Yutaka Sasaki; Hideo Baba
Journal:  Surg Today       Date:  2017-11-07       Impact factor: 2.549

2.  Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma.

Authors:  Michitoshi Takano; Takashi Kokudo; Yoshihiro Miyazaki; Yumiko Kageyama; Amane Takahashi; Katsumi Amikura; Hirohiko Sakamoto
Journal:  World J Gastroenterol       Date:  2016-11-14       Impact factor: 5.742

3.  Pathological complete response by advanced hepatocellular carcinoma with massive macrovascular invasion to hepatic arterial infusion chemotherapy: a case report.

Authors:  Shusei Sano; Shinji Nakata; Shuichi Wada; Masatsugu Kuroiwa; Hiroki Sakai; Kei Kusama; Taiichi Machida; Akihito Nishio; Ichiro Ito; Harutsugu Sodeyama
Journal:  World J Surg Oncol       Date:  2019-12-26       Impact factor: 2.754

4.  Usefulness of a novel transarterial chemoinfusion plus external-beam radiation therapy for advanced hepatocellular carcinoma with tumor thrombi in the inferior vena cava and right atrium: Case study.

Authors:  Tomotake Shirono; Hironori Koga; Takashi Niizeki; Hiroaki Nagamatsu; Hideki Iwamoto; Shigeo Shimose; Masahito Nakano; Shusuke Okamura; Yu Noda; Naoki Kamachi; Ryoko Kuromatsu; Etsuyo Ogo; Takuji Torimura
Journal:  Cancer Rep (Hoboken)       Date:  2021-08-24

Review 5.  Targeted therapy for hepatocellular carcinoma.

Authors:  Ao Huang; Xin-Rong Yang; Wen-Yuan Chung; Ashley R Dennison; Jian Zhou
Journal:  Signal Transduct Target Ther       Date:  2020-08-11

6.  Resection of "down-staged" advanced hepatocellular carcinoma after treatment with the VEGFR2 inhibitor apatinib: five cases report.

Authors:  Zhenyu Hou; Keyun Zhu; Xuejiao Yang; Hongyuan Zhou; Ping Chen; Ge Yu; Xiaolin Zhu; Yunlong Cui; Tianqiang Song; Qiang Li; Huikai Li; Ti Zhang
Journal:  Transl Cancer Res       Date:  2020-08       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.